NEWS SOURCE: Epeius Biotechnologies Corporation
SAN MARINO, CA – June 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.
Rexin-G(TM) is the world’s first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Rexin-G(TM) seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy.
Rexin-G recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN.
In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: “We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which – by improving both the survival and the quality of life – provide cancer patients with more quality time.”
More information: http://www.epeiusbiotech.com
News issued by: Epeius Biotechnologies Corporation
# # #
Original Story ID: (1748) :: 2006-06-0619-001
Original Keywords: Rexin-G, Lazarex Cancer Foundation, clinical trials in the USA and abroad, destroys metastatic cancer, chemotherapy, Dana Dornsife, Dr. Erlinda M. Gordon, Dr. Frederick L. Hall, California, california news Epeius Biotechnologies Corporation
NEWS SOURCE: Epeius Biotechnologies Corporation | Published: 2006-06-19 16:07:00
IMPORTANT NOTICE FOR ARCHIVAL CONTENT ABOVE: The above archival press release content was issued on behalf of the noted "news source" who provided the content (text and image[s]) and is solely responsible for its accuracy. Links may not work if very old; use such with caution. Send2Press does not represent the "news source" in any capacity. For questions about this content contact the company/person mentioned directly. To report fraud or illegal material, or DMCA complaints, please contact Send2Press via our main site (any such complaints must be made in writing, not by phone).
